GlassScriptPhysician profile
Eric Fisher
NPI 1710004502
$5,135.27
in general payments reported to CMS, 2019-2025
27 companies · $351 in 2025
The $351 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $456 · 2020: $620 · 2021: $902 · 2022: $865 · 2023: $1,125 · 2024: $816 · 2025: $351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,292.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,291.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,013.50 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $926.80 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $689.59 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $614.85 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $359.67 | 2020-2025 | Mounjaro, Trulicity, Zepbound |
| Merck Sharp & Dohme LLC | $297.83 | 2019-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Sanofi-Aventis U.S. LLC | $256.20 | 2019-2023 | |
| Daiichi Sankyo INC. | $224.09 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $79.92 | 2023 | Rexulti |
| Abbott Laboratories | $75.33 | 2022-2023 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.95 | 2021-2022 | |
| Pfizer INC. | $68.77 | 2020-2025 | |
| Electronic Waveform Lab, INC. | $57.05 | 2019-2021 | |
| Optinose US, INC. | $52.23 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $52.18 | 2022-2023 | Airduo Digihaler |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $42.36 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.97 | 2025 | Vpriv |
| Grt US Holding, INC. | $29.72 | 2022 | |
| Exact Sciences Corporation | $28.04 | 2023-2024 | Cologuard Collection Kit |
| Amgen INC. | $23.67 | 2024 | Krystexxa |
| Horizon Therapeutics Plc | $21.60 | 2023 | Krystexxa |
| Nevro Corp. | $20.95 | 2022 | |
| Phadia US INC. | $20.78 | 2021 | |
| Tactile Systems Technology INC | $20.27 | 2023 | Entre Plus, Flexitouch Plus |
| Xeris Pharmaceuticals, INC. | $19.85 | 2025 | Gvoke Hypopen |
| Astellas Pharma US INC | $18.55 | 2019 | |
| Gilead Sciences, INC. | $15.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Fisher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.